EKSPERIMENTAL QANDLI DIABETDA JIGAR MIKROSOMAL OKSIDLANISH FENOTIPINING UGLEVOD VA LIPID ALMASHINUVIGA TA'SIRI: SITOXROM P450 FAOLLIGI VA METABOLIK BUZILISHLAR O'RTASIDAGI BOG'LIQLIK
;
https://doi.org/10.5281/zenodo.20823254;
qandli diabet, mikrosomal oksidlanish fenotipi, sitoxrom P450, CYP2E1, uglevod almashinuvi, lipidlar peroksidlanishi, oksidlanishli stress, streptozotsin, jigar metabolizmi, dislipidemiya.Abstrak
Streptozotsin (STZ) bilan keltirilgan eksperimental qandli diabet (QD) modelida jigar mikrosomal oksidlanish fenotipining — tez (TO) va sekin (SO) oksidlovchilarning — uglevod hamda lipid almashinuvi ko'rsatkichlariga qanday ta'sir ko'rsatishini aniqlash. Wistar zotli erkak kalamushlar (n=32) streptozotsin (60 mg/kg, in peritoneumga) yordamida diabetik model shakllantirildi. Antipirin testi asosida hayvonlar TO (n=12) va SO (n=10) subguruhlariga ajratildi, nazorat guruhi (n=10) amalda sog'lom hayvonlardan iborat bo'ldi. Glyukoza, insulin, HbA1c, HOMA-IR, lipidlar spektri, MDA, SOD, katalaza va CYP2E1 aktivligi o'lchandi. Ma'lumotlar Kruskal-Wallis va Mann-Whitney U testlari yordamida tahlil qilindi (SPSS v.26). SO guruhida och qorindagi glyukoza darajasi nazoratga nisbatan 4,3 barobar ortdi (22,4±1,8 vs 5,2±0,3 mmol/L, p<0,001), GTT-120 da normalizatsiya kuzatilmadi. TO guruhida esa CYP2E1 faolligi nazorat qiymatidan 2,8 barobar yuqori chiqdi (1,18±0,09 vs 0,42±0,03 nmol/min/mg), MDA 2,2 barobar, SOD esa 2,3 barobar pasaydi (p<0,001). Lipid spektrida TO guruhida PZLP-XS ustunlik qilsa (4,2±0,3 mmol/L), SO guruhida jigarda diffuz trigliserid to'planishi kuzatildi.Iqtiboslar
International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: IDF; 2021. Available from: https://www.diabetesatlas.org [Accessed 2024 Mar 15].
DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019. doi:10.1038/nrdp.2015.19.
Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;126(1):12-22. doi:10.1172/JCI77812.
Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol. 2008;21(1):70-83. doi:10.1021/tx700079z.
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103-141. doi:10.1016/j.pharmthera.2012.12.007.
Leung TM, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic liver disease. J Hepatol. 2013;58(2):395-398. doi:10.1016/j.jhep.2012.08.018.
Abdelmegeed MA, Song BJ. Functional roles of protein nitration in acute and chronic liver diseases. Oxid Med Cell Longev. 2014;2014:149627. doi:10.1155/2014/149627.
Raza H, John A, Shafarin J. N-Acetylcysteine Attenuates Oxidative Stress and Liver Injury in Streptozotocin-Induced Diabetic Rats. Ann N Y Acad Sci. 2016;1374(1):46-52. doi:10.1111/nyas.13040.
Song X, Qian Y, Chen H, Li X, Li F, Ma L. CYP2E1 promotes hepatic steatosis and inflammatory response by regulating NLRP3 inflammasome activation and autophagy. Biochem Pharmacol. 2020;172:113745. doi:10.1016/j.bcp.2019.113745.
Elsner M, Tiedge M, Lenzen S. Mechanism underlying resistance of human pancreatic beta cells against toxicity of streptozotocin and alloxan. Diabetologia. 2003;46(12):1713-1714. doi:10.1007/s00125-003-1241-x.
Dorne JL, Walton K, Renwick AG. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem Toxicol. 2005;43(2):203-216. doi:10.1016/j.fct.2004.10.002.
Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121-126. doi:10.1016/S0076-6879(84)05016-3.
Kessova I, Cederbaum AI. CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury. Curr Mol Med. 2003;3(6):509-518. doi:10.2174/1566524033479609.
Li F, Lu J, Cheng J, Wang L, Matsubara A, Krausz KW, et al. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med. 2013;19(4):418-420. doi:10.1038/nm.3104.
Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15(1):45. doi:10.1186/s12916-017-0806-8.
Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003;52(6):1364-1370. doi:10.2337/diabetes.52.6.1364.
Guo Y, Cho HY, Whitaker RH, Wan M, He B. CYP2E1 regulation by lipid peroxidation end-products in the context of its own induction. Free Radic Biol Med. 2018;115:92-103. doi:10.1016/j.freeradbiomed.2017.11.022.
Tirmenstein MA, Hu CX, Scully SM, Fariss MW. Effects of succinate on mitochondrial function and extent of lipid peroxidation in vitro. Chem Biol Interact. 1997;105(3):181-193. doi:10.1016/S0009-2797(97)00042-1.
Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther. 2003;73(6):517-528. doi:10.1016/S0009-9236(03)00052-4.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapentaenoic acid for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792.
##submission.downloads##
Nashr qilingan
Nashr
Bo'lim
Litsenziya
##submission.copyrightStatement##
##submission.license.cc.by4.footer##Iqtibos keltirish tartibi
